303 related articles for article (PubMed ID: 37162742)
1. Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder.
Lee M; Abousaud A; Harkins RA; Marin E; Balasubramani D; Churnetski MC; Peker D; Singh A; Koff JL
Curr Oncol Rep; 2023 Aug; 25(8):883-895. PubMed ID: 37162742
[TBL] [Abstract][Full Text] [Related]
2. Epstein Barr virus-directed T-cell therapy for refractory EBV-PTLD in a toddler post Orthotopic heart transplantation.
Work E; Gupta D; Slayton WB; Rees J; Coppola JA; Seifert R; Bleiweis MS; Jacobs JP; Peek G; Philip J; Brock A; Rivera JH; Sullivan K; Narasimhulu SS
Pediatr Transplant; 2024 Mar; 28(2):e14707. PubMed ID: 38419558
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
Ru Y; Chen J; Wu D
Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
[TBL] [Abstract][Full Text] [Related]
5. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
7. Management of post-transplant lymphoproliferative disorders.
Llaurador G; McLaughlin L; Wistinghausen B
Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
Seshadri M; Crane GM; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):68-73. PubMed ID: 32413419
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
Barlev A; Zimmermann H; Guzman-Becerra N; Mehta A; Xing B; Macabeo B; Thivolet M; Brookhart MA
J Med Econ; 2024; 27(1):789-795. PubMed ID: 38727527
[TBL] [Abstract][Full Text] [Related]
10. Clinical Post-Transplant Lymphoproliferative Disorders.
Aghsaeifard Z; Alizadeh R
Cardiovasc Hematol Disord Drug Targets; 2022; 22(2):96-103. PubMed ID: 35927798
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies.
Atallah-Yunes SA; Salman O; Robertson MJ
Br J Haematol; 2023 May; 201(3):383-395. PubMed ID: 36946218
[TBL] [Abstract][Full Text] [Related]
12. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
14. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorders following kidney transplantation: A literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type.
Ergisi M; Ooi B; Salim O; Papalois V
Transplant Rev (Orlando); 2024 Apr; 38(2):100837. PubMed ID: 38430887
[TBL] [Abstract][Full Text] [Related]
17. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV
Chaganti S; Barlev A; Caillard S; Choquet S; Cwynarski K; Friedetzky A; González-Barca E; Sadetsky N; Schneeberger S; Thirumalai D; Zinzani PL; Trappe RU
Adv Ther; 2023 Mar; 40(3):1267-1281. PubMed ID: 36681739
[TBL] [Abstract][Full Text] [Related]
18. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
Jiménez S
Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.
Al Hamed R; Bazarbachi AH; Mohty M
Bone Marrow Transplant; 2020 Jan; 55(1):25-39. PubMed ID: 31089285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]